 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI today provided an update on MARIO-275, the Companys randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab Opdivo in platinum-refractory, IO naïve patients with advanced, metastatic urothelial cancer mUC over nivolumab monotherapy which is approved in this setting. The MARIO-275 study provided Infinity with important insights to shape the future of eganelisib i 